argenx SE (ARGX)

Market Cap	36.33B
Revenue (ttm)	2.25B
Net Income (ttm)	833.04M
Shares Out	60.99M
EPS (ttm)	12.78
PE Ratio	43.61
Forward PE	46.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,076
Open	596.01
Previous Close	593.47
Day's Range	588.97 - 598.06
52-Week Range	352.77 - 678.21
Beta	0.20
Analysts	Strong Buy
Price Target	682.00 (+15.78%)
Earnings Date	May 8, 2025

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 1,599
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX
• Website: https://argenx.com

Analyst Forecast

According to 20 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $682.0, which is an increase of 15.78% from the latest price.

Price Target

$682.0

(15.78% upside)

Analyst Consensus: Strong Buy